We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Immunomedics (IMMU) in Focus: Stock Moves 5% Higher
Immunomedics, Inc. was a big mover last session, as the company saw its shares rise nearly 5% on the day. This stock, which remained volatile and traded within the range of $9.48 – $17.16 in the past one-month time frame, witnessed a sharp increase yesterday.
The company has seen one negative estimate revision in the past two months, while its Zacks Consensus Estimate for the current quarter has also moved lower in the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Immunomedics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Immunomedics, Inc. Price
Immunomedics, Inc. price | Immunomedics, Inc. Quote
A better-ranked stock in the Medical – Biomedical and Genetics industry is Acorda Therapeutics, Inc. , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>